The translational value of the MPTP non-human primate model of Parkinsonism for deep brain stimulation research

2011 ◽  
Author(s):  
Peter A. Tass ◽  
Li Qin ◽  
Christian Hauptmann ◽  
Sandra Dovero ◽  
Erwan Bezard ◽  
...  
Keyword(s):  
Deep Brain Stimulation ◽  
Brain Stimulation ◽  
Primate Model ◽  
Human Primate ◽  
Deep Brain

scholarly journals The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine–induced parkinsonism

2009 ◽  
Vol 110 (2) ◽  
pp. 234-238 ◽  
Author(s):  
Chadwick W. Christine ◽  
J. William Langston ◽  
Robert S. Turner ◽  
Philip A. Starr
Keyword(s):  
Deep Brain Stimulation ◽  
Brain Stimulation ◽  
Drug Users ◽  
Nonhuman Primates ◽  
Symptomatic Therapy ◽  
Unique Case ◽  
Primate Model ◽  
Significant Clinical Improvement ◽  
Mptp Model ◽  
Deep Brain

Parkinsonism caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) exposure was first identified in intravenous drug users. This neurotoxicant has since been used extensively in nonhuman primates to induce an experimental model of Parkinson disease (PD). In this study, the authors examined the intraoperative physiological characteristics and efficacy of subthalamic nucleus deep brain stimulation (DBS) in 1 of only 4 known living patients with MPTP-induced parkinsonism. The physiological recordings were consistent with recordings from MPTP-treated primates and humans with PD, thus providing further validation for the MPTP model in the study of the neurophysiology of the nigrostriatal dopaminergic deficit in PD. Furthermore, DBS produced a significant clinical improvement in this patient similar to the improvement seen after DBS in patients with idiopathic PD. This unique case has important implications for translational research that employs the MPTP-primate model for symptomatic therapy in PD.

scholarly journals Closed-Loop Deep Brain Stimulation Effects on Parkinsonian Motor Symptoms in a Non-Human Primate – Is Beta Enough?

2016 ◽  
Vol 9 (6) ◽  
pp. 892-896 ◽  
Author(s):  
Luke A. Johnson ◽  
Shane D. Nebeck ◽  
Abirami Muralidharan ◽  
Matthew D. Johnson ◽  
Kenneth B. Baker ◽  
...  
Keyword(s):  
Deep Brain Stimulation ◽  
Brain Stimulation ◽  
Closed Loop ◽  
Motor Symptoms ◽  
Human Primate ◽  
Deep Brain

Deep brain stimulation of the pedunculopontine region in the normal non-human primate

2002 ◽  
Vol 9 (2) ◽  
pp. 170-174 ◽  
Author(s):  
Dipankar Nandi ◽  
Xuguang Liu ◽  
Jonathan L. Winter ◽  
Tipu Z. Aziz ◽  
John F. Stein
Keyword(s):  
Deep Brain Stimulation ◽  
Brain Stimulation ◽  
Human Primate ◽  
Deep Brain ◽  
Stimulation Of

Nicht-medikamentöse Optionen zur Behandlung pharmakoresistenter Epilepsien

2018 ◽  
Vol 75 (7) ◽  
pp. 448-454
Author(s):  
Thomas Grunwald ◽  
Judith Kröll
Keyword(s):  
Deep Brain Stimulation ◽  
Brain Stimulation ◽  
Tiefe Hirnstimulation ◽  
Ketogene Diät ◽  
Deep Brain

Zusammenfassung. Wenn mit den ersten beiden anfallspräventiven Medikamenten keine Anfallsfreiheit erzielt werden konnte, so ist die Wahrscheinlichkeit, dies mit anderen Medikamenten zu erreichen, nur noch ca. 10 %. Es sollte dann geprüft werden, warum eine Pharmakoresistenz besteht und ob ein epilepsiechirurgischer Eingriff zur Anfallsfreiheit führen kann. Ist eine solche Operation nicht möglich, so können palliative Verfahren wie die Vagus-Nerv-Stimulation (VNS) und die tiefe Hirnstimulation (Deep Brain Stimulation) in eine bessere Anfallskontrolle ermöglichen. Insbesondere bei schweren kindlichen Epilepsien stellt auch die ketogene Diät eine zu erwägende Option dar.

Sign in / Sign up

Export Citation Format

Share Document